Serum miR-21 putative biomarker for colorectal cancer

Serum <i>miR-21</i> putative biomarker for colorectal cancer
The oncogenic microRNA miR-21 is a potential biomarker for detection and prognosis of colorectal cancer, according to a study published in the June 19 issue of the Journal of the National Cancer Institute.

(HealthDay)—The oncogenic microRNA (miRNA) miR-21 is a potential biomarker for detection and prognosis of colorectal cancer (CRC), according to a study published in the June 19 issue of the Journal of the National Cancer Institute.

Yuji Toiyama, from the Baylor University Medical Center in Dallas, and colleagues screened for expression of miR-21 and miR-31 in two CRC cell lines and in serum from 12 patients with CRC and 12 controls. Expression of candidate miRNAs was validated in serum samples from an independent cohort of 186 patients with CRC, 60 postoperative patients, 43 patients with advanced adenoma, and 53 controls. To determine whether serum miRNAs reflect expression in CRC, miR-21 expression was analyzed in 166 matched primary CRC tissues.

The researchers found that miR-21 was secreted from CRC cell lines and upregulated in serum from CRC patients. In patients with adenomas and CRCs from the validation cohort, miR-21 expression was significantly elevated in preoperative serum, and expression decreased in postoperative serum from patients who underwent curative surgery. Serum miR-21 levels differentiated patients with adenoma and CRC from control patients (area under the curve, 0.813 and 0.919, respectively). There was a significant correlation between high serum and tissue miR-21 expression with , distant metastases, and poor survival. Serum miR-21 was a significant for CRC, with a hazard ratio of 4.12.

"Our results provide compelling evidence for the potential usefulness of serum miR-21 as a noninvasive screening and prognostic tool in patients with , a concept that can be incorporated into routine clinical practice in the not-so-distant future pending validation in large-scale prospective trials," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Comprehensive discussion with docs ups cancer screening

Apr 29, 2013

(HealthDay)—Having more comprehensive discussions about colorectal cancer (CRC) screening with primary care providers (PCPs) is associated with increased odds of screening, according to a study published ...

Recommended for you

Gene test aids cancer profile

11 hours ago

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.